Semin Thromb Hemost 2000; Volume 26(Number 01): 097-100
DOI: 10.1055/s-2000-9810
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4663)

Whole Blood Prothrombin Time Using Diluted Tissue Factor is Shortened in Spontaneous Hypertensive Rats

Machiko Munakata1 , Yutaka Komiyama1 , Midori Masuda1 , Hideo Kagawa2 , Shosaku Nomura2 , Shirou Fukuhara2 , Hakuo Takahashi1
  • Supported in part by a grant-in-aid for scientific research from the Japanese Ministry of Education, Science and Culture.
  • 1Department of Clinical Sciences and Laboratory Medicine, Kansai Medical University, Moriguchi, Osaka, Japan
  • 2The First Department of Internal Medicine, Kansai Medical University, Moriguchi, Osaka, Japan
Further Information

Publication History

Publication Date:
31 December 2000 (online)

 

ABSTRACT

Clinical screening tests for blood coagulation that use plasma as samples cannot estimate the participation of platelets, leukocytes, and erythrocytes in blood coagulation system. We developed an assay to evaluate the total coagulation ability of blood and whole blood prothrombin time (WPT) using the principle of prothrombin time with the diluted-tissue factor as a trigger and a newly developed apparatus, STA, viscosity change detection system (electromagnetic clot detection). The activation of platelets by Ca ionophore shortened WPT and increased the expression of CD62P on the platelet surface. WPTs in citrated blood of spontaneous hypertensive rats (SHR) were significantly shorter than those of controls, Wistar Kyoto rats (WKY). Plasma levels of thrombin-antithrombin III (TAT) in SHR were significantly higher than those of WKY. Moreover, WPT and TAT levels were significantly correlated. Based on these results, WPT was found to be useful to estimate the activation of blood coagulation in whole blood.

REFERENCES

  • 1 Bowie E JW, Owen Jr A C. Clinical and laboratory diagnosis of hemorrhagic disorders. In: Ratnoff OD, Forbes CD, eds Disorders of Hemostasis, Philadelphia: Saunders 1991: 48-74
  • 2 Hellstern P, Faller B, Haas F L M J. Multicenter evaluation of the STA analyzer.  Klin Lab . 1994;  40 509-522
  • 3 Komiyama Y, Munakata M, Masuda M. Evaluation of prothrombin time with use of highly diluted tissue factor reagents.  Jpn J Thromb Haemost . 1997;  8 376-381
  • 4 Murakami T, Komiyama Y, Masuda M. Evaluation of factor XIa-α1 antitrypsin in plasma, a contact phase activated coagulation factor-inhibitor complex, in patients with coronary artery disease.  Arterioscler Thromb Vasc Biol . 1995;  15 1107-1113
  • 5 Komiyama Y, Tomii A, Mori T. Production of ouabain-like factors of hypothalamo-pituitary origin, determined by a sensitive ELISA for ouabain, is increased in DOCA-salt hypertensive rats.  Pathophysiology . 1995;  2 35-40
  • 6 Murakami T, Komiyama Y, Masuda M. Flow cytometric analysis of platelet activation markers, CD62P and CD63, in patients with coronary artery disease.  Eur J Clin Lab Med . 1996;  26 996-1003
  • 7 MacCarron R M, Doron D A, Siren A L. Agonist-stimulated release of von Willebrand factor and procoagulant factor VIII in rats with and without risk factors for stroke.  Brain Res . 1994;  647 265-272
  • 8 Rand T D, Lock J B, van't Veer C, Gaffney D P, Mann K G. Blood clotting in minimally altered whole blood.  Blood . 1996;  88 3432-3445
  • 9 Komiyama Y, Pedersen A H, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: Effects of calcium, phospholipids and tissue factor.  Biochemistry . 1990;  29 9418-9425
  • 10 Amirkhosravi A, Biggerstaff J P, Warnes G, Francis D A, Francis J L. Determination of tumor cell procoagulant activity by SonoclotTM analysis in whole blood.  Thromb Res . 1996;  84 323-332
  • 11 Koyama T, Nishida K, Ohdama S. Determination of plasma tissue factor antigen and its clinical significance.  Br J Haematol . 1994;  87 343-347
    >